25 Nov 2024 • The IRIS-TNK registry confirms that tenecteplase, administered at a dose of 0.2 mg/kg within 4.5 hours of symptom onset, is safe for use in routine clinical practice for treating acute ischemic stroke.

The study, involving 1,015 patients across India, revealed a low incidence of symptomatic intracerebral hemorrhage (0.6%) and a relatively low 3-month mortality rate (1%).

Additionally, the treatment showed promising functional outcomes: 34.4% of patients exhibited a significant improvement in their NIHSS score, and 55.4% achieved an excellent outcome within 3 months.

These findings provide strong evidence supporting tenecteplase’s safety and efficacy when used in real-world clinical settings, aligning with previous research while offering more extensive data in the Indian population. The results reassure clinicians of tenecteplase’s role in improving stroke outcomes with minimal adverse effects.

Source: Journal of the American Heart Association | Read full story